Table 6.
Management of febrile neutropenia among 405 adult patients with cancer treated in the Northwest Ethiopia oncology centers
| FN management | Specific treatment | n (%) |
|---|---|---|
| Anti-bacterial used (n = 405) | Ceftazidime + vancomycin | 124 (30.7) |
| Cefepime + vancomycin | 65 (16.1) | |
| Vancomycin + meropenem | 47 (11.6) | |
| Ceftazidime + gentamicin | 46 (11.4) | |
| Ceftazidime + ciprofloxacin | 43 (10.6) | |
| Cefepime | 31 (7.6%) | |
| Ceftazidime | 22 (5.4) | |
| Meropenem | 18 (4.4) | |
| Ceftriaxone | 9 (2.2) | |
| Anti-bacterial therapeutic regimen (n = 405) | Combination therapy | 325 (80.3) |
| Monotherapy | 80 (19.7) | |
| Antibacterial prophylaxis (n = 91) (22.5%) | Ciprofloxacin | 45 (11.1) |
| Levofloxacin | 31 (7.7) | |
| Cotrimoxazole | 15 (3.7) | |
| Antifungal therapy | Yes | 137 (33.8) |
| No | 268 (66.2) | |
| Antiviral therapy | Yes | 52 (12.5) |
| No | 353 (87.2) | |
| Filgrastim use | Yes | 229 (56.5) |
| No | 176 (43.5) |
FN Febrile neutropenia